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Abstract
Background: Palliative radiotherapy (RT) is an effective treatment for symptomatic bone metastases. Pain flare, a
transient worsening of the bone pain after RT, has been described in previous reports with different incidence rates.
The aim of the study was to prospectively evaluate the incidence of pain flare following RT for painful bone
metastases and evaluate its effects on pain control and functionality of the patients.
Methods: Between June 2010 and June 2014, 204 patients were enrolled in this study and 135 patients with
complete data were evaluable. Pain flare was defined as a 2- point increase in worst pain score as compared with
baseline with no decrease in analgesic intake or a 25 % increase in analgesic intake as compared with baseline with
no decrease in worst pain score. All pain medications and worst pain scores were collected before, daily during,
and for 10 days after RT. The Brief Pain Inventory (BPI) was filled out on the pretreatment and at the 4 weeks
follow-up visit.
Results: There were 90 men (66.7 %) and 45 women (33.3 %). Mean age was 66 years (SD 9.8). The most common
primary cancer site was lung in 42 patients (31.1 %), followed by prostate in 27 patients (20.0 %). Forty-two patients
(31.1 %) patients received a single fraction of 8 Gy and 83 (61.5 %) received 20 Gy in five fractions.
The overall pain flare incidence across all centers was 51/135 (37.7 %). The majority of pain flares occurred on days
1–5 (88.2 %). The mean duration of the pain flare was 3 days (SD: 3). There were no significant relationships
between the occurrence of pain flare and collected variables.
All BPI items measured four weeks after end of RT showed significant improvement as compared with pretreatment
scores (p < 0.001). No significant differences in BPI time trends were found between patients with and without flare pain.
Conclusion: Pain flare is a common event, occurring in nearly 40 % of the patients that receive palliative RT for
symptomatic bone metastases. This phenomenon is not a predictor for pain response.
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Background
Bone metastases are a common distance manifestation
in advanced oncologic patients with a rising incidence
due to longer survival of cancer patients. It is the most
common cause of cancer-related pain and the most fre-
quent symptom that requires treatment in cancer
patients [1].
Palliative radiotherapy (RT) is a well-established and
effective treatment alternative for symptomatic bone me-
tastases. Depending on the criteria used, complete re-
sponse of the pain could be achieved from 10 % to 35 %
of patients, with overall pain response rates approaching
70 % [2].
Several randomized controlled trials (RCT) [3–7] and
three meta-analysis [8–10] have shown equivalent pain
response rates for single- and multiple-fraction radio-
therapy treatments in the palliation of painful bone
metastases.
Although RT for bone metastases is associated with
limited side effects, a transitory aggravation of bone pain
after treatment in the irradiated site has been recognized
in several published reports, with published incidence
rates of this phenomenon varying between 2 % and 40 %
[11–13].
To date, the evidence in the literature evaluating pro-
spectively the incidence of pain flare is scarce. Few pro-
spective observational studies, with a low number of
patients, have explored the incidence of pain flare [12,
14]. These studies have also demonstrated that pain flare
associated with RT negatively impacts on the functional-
ity and the mood of the patients.
Therefore, the objectives of this prospective multi-
center observational study were to determine the inci-
dence of pain flare after palliative radiation for painful
bone metastases and to evaluate the impact of the pain
flare on the pain control and the functionality of the
patients.
Methods and Materials
Subjects eligible for the study were patients with bone
metastases treated with External Beam RT. Criteria for
patient eligibility were: age 18 years or older with radio-
logical evidence of bone metastases from a solid tumor,
single lesion or multiple metastases were both accepted,
pain intensity attributable to the bone lesion measured
by Visual Analogue Scale (VAS) of 0–10 and patients
capability and willingness to sign informed consent and
complete the daily diary.
The radiation dose schedules permitted in the study
were those administering 8 to 20 Gy in 1 to 5 daily
fractions.
The protocol was initially approved by the Ethics
Committee of the coordinating center (Hospital Univer-
sitario Cruces ), and ethics approval was subsequently
requested and obtained at each participating center
(Hospital Ramón y Cajal, Hospital Meixoeiro, Hospital
Universitario Virgen de la Macarena, Hospital Gregorio
Marañon, ICO- Instituto Catalan de Oncologia, Hospital
Universitario Reina Sofia, Hospital Provincial Castellon,
Hospital Sanchinarro, Hospital Virgen del Rocio).
Patient evaluation
The pre-treatment evaluation consisted of a full history
and physical examination, administration of Brief Pain
Inventory (BPI), record of analgesic consumption within
the previous 24 h and provision of the patient´s diary
with oral and written instructions on how to fill it on a
daily basis during treatment and 10 days after termin-
ation of RT. This diary recorded worst pain scores (on a
numerical rating scale from 0–10), analgesic usage (total
intake of analgesic medication in the 24 hour-period)
and pain perception as compared with baseline pain
(worse, better or same).
A follow-up visit was scheduled 4-weeks after the end
of the RT. At this time the BPI was again administered,
and analgesic consumption within the previous 24 hours
was recorded.
Treatment response
Pain response was measured using the International
Bone Metastases Consensus from 2002 [15]. Complete
response was defined as a pain score of zero at the bony
metastatic site with no concomitant increase in analgesic
intake. Partial response was defined as any of the follow-
ing: a) pain reduction of two or more points below base-
line score, at the bony metastatic site on a 0–10 scale
without analgesic increase or b) analgesic reduction of
25 % or more from baseline without an increase in pain
with reference to baseline. Pain progression was defined
as an increase of pain score of two or more points above
baseline at the bony metastatic site with stable analgesic
use or an increase of 25 % or more daily OMED com-
pared with baseline with pain score stable or one point
above baseline. Patients not meeting these criteria were
classified as having stable disease.
Pain flare evaluation
Since most previous studies concerning pain flare have
used the definition by Chow [11], we also chose to use
this definition in order to enable comparisons with other
studies.
Pain flare was defined (a priori) as any two-point in-
crease of the pain scale of 0–10 in the daily diary com-
pared to baseline levels with no decrease in analgesic
intake or a 25 % increase in analgesic intake employing
daily OMED with no decrease in pain score. If the base-
line pain was nine, pain flare was defined if the follow
up pain score was 10 accompanied with a response of
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current pain perception worse than the baseline pain. If
the baseline pain was 10, pain flare was defined if the
follow up pain score was 10 with current pain percep-
tion as worse than the baseline pain. To distinguish pain
flare from progression of pain, we required the pain
score and analgesic intake to return back to baseline
after the flare [11].
Statistical analysis
Descriptive statistics were used for demographic, clinical
and treatment characteristics.
Continuous variables are expressed as the mean and
standard deviation or median and range for quantitative
variables, depending on distributional characteristics,
whereas categorical variables are presented as frequen-
cies and percentages.
Associations between categorical variables were assessed
using Chi square or Fisher exact tests depending upon ex-
pected cell frequencies.
To assess changes in BPI items scoring between
follow-up and baseline visit, T-tests for paired samples
were used. To compare changes of BPI scores over time
between patients with and without pain flare, T-tests for
independent samples were used. All statistical analyses
were conducted using SPSS v22 for Windows (IBM
Corp. Released 2013. IBM SPSS Statistics for Windows,
Version 22.0. Armonk, NY: IBM Corp). Statistical sig-
nificance threshold was set at 5 %.
Results
Between June 2010 and June 2014, 204 patients from ten
Radiation Oncology Departments in Spain participated
in this prospective observational study. From this cohort,
135 patients (66.2 %) completed the daily diary, 127 pa-
tients (62.2 %) the 4-weeks follow-up visit and 118 pa-
tients (57.8 %) completed both, the daily diary and the
follow-up visit. These patients are labeled as evaluable
patients and are the subject of statistical analysis. Rea-
sons for incomplete data are: 25 patients experienced a
deterioration in their performance status, 21 patients did
not complete the pain diary, there were 16 unknown
reasons for incomplete data and 15 patients requested
removal from the study.
The relevant demographic, clinical and treatment
characteristics of evaluable and no evaluable patients are
shown in Table 1.
Based on the Chow definition [11], 51 of the 135 eva-
luable patients (37.7 %) presented pain flare. Pain flare
occurred between days 1–5 after RT in 45/51 patients
(88.2 %) and between days 6–15 in 6/51 patients
(11.8 %) (Fig. 1). The mean duration of the flare was
3 days (SD 3).
Table 1 Main demographic, clinical and treatment characteristics.
Evaluable Patients (N = 135) No Evaluable Patients (N = 69)
Age (years) Mean (SD) 66.6(12.4) 65.6(11.1)
Gender Male 90 (66.7 %) 45(65.2 %)
Female 45 (33.3 %) 24(34.8 %)
Primary cancer site Lung 42 (31.1 %) 21(30.4 %)
Prostate 27 (20.0 %) 10(14.5 %)
Breast 19 (14.1 %) 5(7.3 %)
Others 47 (34.8 %) 33(47.8 %)
Worst paina Median (range) 8 (0–10) 8 (0–10)
RT dose 5 x 400 cGy 83 (61.5 %) 40(58.0 %)
1 x 800 cGy 42 (31.1 %) 20(29.0 %)
Other 10 (7.4 %) 9(13.0 %)
RT site Pelvis 57 (42.2 %) 21(32.8 %)
Spine 39 (28.9 %) 25(39.1 %)
Extremities 20 (14.8 %) 11(17.2 %)
Others 19 (14.1 %) 7(10.9 %)
Bisphosphonates YES 36 (26.7 %) 16(23.2 %)
NO 99 (73.3 %) 53(76.8 %)
Dexamethasone YES 41 (30.8 %) 17(26.6 %)
NO 92 (69.2 %) 47(73.4 %)
Abbreviations: RT = radiotherapy
aWorst pain recorded using the Brief Pain Inventory (BPI): ranged from 0–10
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Pain response to RT at 4 weeks was available for
127 of the 135 assessable cases. Fifteen patients
(11.8 %) achieved a complete response and 64
(50.4 %) a partial response. Stable disease was found
in 34 patients (26.8 %) and pain progression in 14
(11 %).
No significant relationships were found between the
occurrence of pain flare and baseline variables, such as
gender type, radiation dose, radiation site, primary can-
cer site, bisphosphonates use and dexamethasone use
(Table 2).
Changes in the BPI scores were assessed at 4 weeks
after RT. For evaluation purposes, the BPI responses
were assigned to two different dimensions, pain sever-
ity (sensory dimension of the pain) and pain interfer-
ence (reactive dimension). There was a significant
reduction in all BPI scores after RT (p < 0.001). A
median decrease of 4 points compared to the pre-
treatment setting was found for the “worst pain”,
“activity”, “mood”, “walking ability” and “normal
work” domains.
There were not significant differences in BPI
changes between baseline and 4 weeks follow-up visits
between patients with or without flare effect.
The BPI scores for those who responded (CR or PR)
were compared with those who did not respond (SD or
PD) to RT. There was a significant difference between the
two groups in all functional interference items (p < 0.05)
except for sleep (p = 0.549).
At 4 weeks, 70.8 % of evaluable patients with pain flare
and 58.6 % of evaluable patients without flare were re-
sponders, respectively (p = 0.174).
Fig. 1 Distribution of pain flare events from the date of initiation of Radiotherapy
Table 2 Relationships between the occurrence of pain flare and baseline variables (n = 135)
FLARE
NO YES
N (%) N (%) p-value*
Sex Male 55 (61.1 %) 35 (38.9 %) p = 0.706
Female 29 (64.4 %) 16 (35.6 %)
Cancer Site Lung 23 (54.8 %) 19 (45.2 %) p = 0.358
Prostate 16 (59.3 %) 11 (40.7 %)
Breast 15 (78.9 %) 4 (21.1 %)
Others 30 (63.8 %) 17 (36.2 %)
Bisphosphonates YES 23 (63.9 %) 13 (36.1 %) p = 0.810
NO 61 (61.6 %) 38 (38.4 %)
RT Dose 8 Gy/ 1 fx 28 (66.7 %) 14 (33.3 %) p = 0.091
20 Gy / 5 fx 47 (56.6 %) 36 (43.4 %)
Other 9 (90.0 %) 1 (10.0 %)
Dexamethasone during RT YES 25 (56.1 %) 18 (43.9 %) p = 0.379
NO 59 (64.1 %) 33 (35.9 %)
Abbreviations: RT: radiotherapy; Fx: fraction
*p-value: chi-square/Fisher exact test
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Discussion
This multisite prospective observational study shows
that pain flare is a common event after palliative RT for
painful bone metastases, affecting to almost 40 % of
these patients. To our knowledge the current study is,
up to the present time, the largest clinical cohort pro-
spectively followed to determine the incidence and
characterize the pain flare phenomenon. The use of a
well-defined pain flare definition and the use of OMED
values and verbal description of the pain in our investi-
gation may have improved our capacity to identify a flare
when compared with previous studies [13, 16].
Published articles have reported a wide range of the
flare phenomenon, which vary between 2 % and 40 %.
This difference could be at least partly explained by in-
consistent definitions of pain flare, use of different radi-
ation dose schedules, lack of adjustments for steroid
medication or opiate medication, and variations in the
time periods at which pain intensity was recorded to
capture the flare event [17].
There are several reports [11, 12, 14, 17] specifically
aimed at determining the incidence of pain flare
(Table 3). Three of these studies used conventional
3DCRT and one of them stereotactic body radiation
therapy (SBRT). While on the studies using 3DCRT the
incidence was approximately 40 % [12, 14], the incidence
in the study using SBRT was 68.3 %. This large differ-
ence in the incidence of pain flare has been postulated
to be a result of significantly greater biologically effective
doses delivered with SBRT [17].
A study published by Pan et al. [18], found in a sec-
ondary analysis of single-institution phase 1/2 trials
evaluating SBRT for the treatment of spinal metastases
an overall incidence of flare after SBRT for spinal metas-
tases of 23 %. A significant limitation of this study is that
the trials were designed to investigate longer term
symptomatic and tumor control outcomes instead of
acute pain flare; hence, comparison between the studies
is limited by differences in study design and population.
Moreover, a recent study examining the Mayo Clinic ex-
perience of patients treated with SBRT to non-spine
bony metastasis, found that only 10 % of the patients
presented pain flare. Unfortunately, the flare defin-
ition used, the analgesic consumption pattern and the
number of patients that received corticosteroids are
unknown [19].
The pain flare incidence observed in the studies men-
tioned is higher than might be expected from clinical ex-
perience. In the study published by Chow et al. [11],
there was an occurrence of 2 %-16 %, but subsequent re-
ports by Loblaw et al. [12] and by Hird et al. [14] dem-
onstrated pain flare rates of 40 %. This is comparable to
what we have found in our study.
Based on our results apparently the advent of the pain
flare is more common in the first days after the initiation
of RT. Indeed, the flare occurred between days 1–5 after
RT in 45/51 patients (88.2 %) and between days 6–15 in
6/51 patients (11.8 %). Hird et al. [14] reported similar
results with 80 % of the patients presenting the flare
within days 1–5 after the RT.
The physiopathology of the pain flare is largely un-
known. It has been suggested to arise through edema of
the periostium of the irradiated bone resulting in nerve
compression or the release of inflammatory cytokines
[20]. Thus, dexamethasone has shown potential for pre-
venting this event. Two phase II studies, reporting on
the effect of dexamethasone on the incidence of pain
flare have been published [21, 22]; both studies reported
rates of 24 % and 22 % respectively. In addition, recently,
a phase III trial from Egypt has been published investi-
gating the role of dexamethasone to prevent the flare
phenomenon. They reported significant differences
Table 3 Published studies evaluating prospectively the incidence of Pain Flare
Author Number of evaluable patients RT technique RT dose schedules (Gy/fx) Pain Flare Incidence (%)
Chow 88 3DCRT 8 Gy / 1fx 2 – 16 %
20 Gy 5 fx
30 Gy /10 fx
Loblaw 44 3DCRT 8Gy / fx 40.9 %
20 Gy/ 5 fx
Hird 111 3DCRT 8 Gy / 1 fx 40 %
20 Gy 5 fx
30 Gy /10 fx
Chiang 41 SBRT 20-24 Gy / 1 fx 68.3 %
24–35 Gy / 2–5 fx
Gomez-Iturriaga 135 3DCRT 8Gy / fx 37.7 %
20 Gy/ 5 fx
Abbreviations: 3DCRT: Tridimensional Conformal Radiotherapy: SBRT: Stereotactic Body Radiotherapy
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between groups, 16.2 % incidence in the dexametha-
sone group versus 38 % in the group without steroids
(p = 0.0033) [23]. By contrast, in our study we have
not found differences in pain flare incidence in favor
of the patients who received corticosteroids. In order
to explain these divergent findings, we must first ac-
knowledge that our observational study was not spe-
cifically designed to address this issue. Moreover, less
than half of our population received dexamethasone
during RT (Table 2).
There is an ongoing RCT comparing two different
dose schedules of dexamethasone and placebo led by
the University Medical Center Utrecht. With an ac-
crual goal of 411 patients, this study will help eluci-
date whether dexamethasone is an effective option in
the prevention of pain flare after palliative radiother-
apy for bone metastases [24].
Regarding pain response to RT, we found similar re-
sponse rates to those reported by a range of RCT evalu-
ating response to RT with different dose schedules. Foro
[16], Chow [2], Hartsell [25] and Van der Linden [26] re-
ported complete response rates ranging between 11 %
and 25 %, partial responses between 26 % and 52 %, and
overall response rates between 46 % and 72 %. Despite
the elevated incidence of flare our results demonstrate
12 % of complete responses and 50 % of partial
responses.
A secondary objective of our study was to evaluate
the impact of the palliative radiotherapy on the pain
control and the functional ability of the patients. The
BPI is a well-known instrument, and has been shown
to be a reliable and valid tool in depicting pain sever-
ity and the extent to which pain from bone metasta-
ses interferes with patient functioning. In the present
study, significant changes in all BPI scores were found
over time, decreasing from baseline to week 4.
Nguyen et al. [27] found in a study evaluating pain
response and interference using BPI at 1, 3 and
6 months, that mood was significantly improved in
patients responding to RT and a trend in improve-
ment was observed for general activity and normal
work. Another study by Wu et al. [28], in 109 pa-
tients who completed BPI after palliative RT for pain-
ful bone lesions at 4 and 6 weeks, reported a
reduction for all seven functional interference items,
with greatest improvement in general activity.
In our study we have found a significant difference in
all BPI items after RT (p < 0.001) with larger difference
(4 points) for the “activity”, “mood”, “walking ability”
and “normal work” domains.
Most importantly, these observed significant differ-
ences in BPI items after RT have real impact on quality
of life (QOL) and function, and provide clinically mean-
ingful data to guide clinical decision-making [29].
In the interpretation of this study some limitations are
acknowledged. These include a small sample size of 204
patients recruited and a reduction of the effective sample
for final analysis to 135 patients. Loss to follow-up is a
common problem in patients with metastatic disease.
Furthermore, the limited BPI follow-up of 4 weeks after
radiation impedes evaluation of long-term outcomes.
Our study demonstrates that pain flare is a common
event in patients that receive palliative RT for bone me-
tastases. Despite its frequency, it does not seem to have
detrimental effect on the degree of pain control at
4 weeks. Our study has shown high rates of pain re-
sponse and more importantly, a significant improvement
on the functional interference dimension. Further stud-
ies evaluating whether simple interventions, such as
prophylactic dexamethasone or short-acting opioids con-
tribute to the prevention or amelioration of the flare
phenomenon are warranted.
Conclusion
Pain flare is a common event, occurring in almost 40 %
of the patients that receive palliative RT for symptomatic
bone metastases. RT for symptomatic bone metastases is
a very effective palliative treatment, in terms of pain
control and functional interference, even if the patient
experiences in the short-term a pain flare.
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